Introduction: The attention of scientists from many countries is focused on hormonal substances - adipokines at the present time. Lowering the level of the hormone adiponectin plays a central role in the development of obesity and cardiovascular disease in humans. The aim of the work is to determine the effect of complex therapy of thiotriazolin and L-lysine escinate on adipocyte secretion indices in patients with non-alcoholic fatty liver disease (NAFLD) with overweight and obesity. Materials and methods: 135 patients with overweight and obesity were examined, 46 of which were overweight (BMI-25-29.9 kg / m2), 34 were obesity grade I (BMI-30-34.9 kg / m2), 20 - Obesity II degree (BMI-35-39.9 kg / m2). 35 patients had normal body mass (BMI 18-24.9 kg / m2). We also examined 20 practically healthy persons. The age of the examinees varied, the median age was 55 years (intercourt scale Q1-Q3 from 40 to 61 years). The verification of the diagnosis of NAFLD was conducted in accordance withthe recommendations of the Unified Clinical Protocol. Results: The additional use of thiotriazolin and L-lysine escinate significantly influenced the adiponectin concentration level. Compared with the period before treatment, the adiponectin level increased in patients with overweight and obesity in 1,6 times (p <0.05). Compared to baseline, the adiponectin content in patients with NAFLD increased by 24.6-27.6% (p <0.05). Also, the level of leptin decreases significantly in patients with overweight and obesity (p <0.05). Conclusions: Integrated therapy with thiotriazolin and L-lysine escinate is an effective way to normalize the level of adipokines in patients with NAFLD with overweight and obesity.
Annotation. The aim of the study was to examine the differences in lipid, carbohydrate metabolism and renal function in patients with type 1 diabetes (T1D) with different levels of albumin in the urine depending on the level of cystatin C. The sample was 78 men and 62 women aged 22-26 years, T1D patients. The control group consisted of 8 almost healthy men and 13 almost healthy women of the same age. The level of microalbuminuria and cystatin C was determined in all patients by enzyme-linked immunosorbent assay. Biochemical evaluation of fasting glucose, fasting blood glucose, glucose 2 h after exercise, mean value of glucose, glycated hemoglobin, total cholesterol, triglycerides, GFR according to Cockcroft-Gault, CKD EPI and GFR according to cystatin C. Statistical processing of the obtained results was performed in the license package “Statistica 5.5”, using non-parametric evaluation methods. In T1D patients compared to the control group found significantly higher values – fasting blood glucose, glucose 2 hours after exercise, the average value of glucose, glycated hemoglobin, total cholesterol and triglycerides, cystatin C and lower values – international normal ratio, GFR according to Cockcroft-Gault, GFR by CKD EPI and GFR by cystatin C. With increasing levels of albumin in urine in patients with cystatin C<0.9, there were changes in the following indicators: higher values of total cholesterol in men with proteinuria compared to men with normo- and microalbumin ; and lower values – the international normal ratio in women with microalbuminuria, compared with women with normoalbuminuria; Cockcroft-Gault GFR in men with proteinuria and GFR by CKD EPI in men with proteinuria and microalbuminuria compared to men with normoalbuminuria. With increasing levels of albumin in the urine in patients with cystatin C>0.9 there were changes in the level of the following indicators: higher values – fasting blood glucose and triglycerides in women with proteinuria compared with women with normoalbuminuria, and glycated hemoglobin and total cholesterol compared with and microalbuminuria; international normal ratio in men with microalbuminuria, compared with men with normoalbuminuria; and smaller values – GFR level by Cockcroft-Gault in men with microalbuminuria compared to men with normoalbuminuria; GCF levels by Cockcroft-Gault in women with proteinuria compared to women with microalbuminuria and GFR levels by CKD EPI in women with proteinuria compared to women with normoalbuminuria and microalbuminuria. With increasing levels of cystatin C, a decrease in glycated hemoglobin in men and women with microalbuminuria and triglycerides in women with microalbuminuria, as well as greater values of the international normal ratio in men with normoalbuminuria and GFR on cystatin C in men and women with normoalbuminuria and micro. Thus, the study obtained results that indicate the existence of differences in the studied indicators between healthy and sick subjects, between men and women and between groups of T1D patients’ men or women with different levels of albumin and cystatin C.
The effect of morning and evening administrations of melatonin on structural and functional changes in the large intestine of rats with obesity under conditions of the spring-autumn photoperiod (12L:12D) was studied in this work. The obesity was caused with a high-calorie diet for 6 weeks. After that, the morning or evening melatonin administrations were given to normal and obese animals at a dose of 30 mg/kg for 7 weeks. After 13 weeks, two specimens of the colon 1 cm each were taken at a distance of 3 cm from the anus; fixed in 10% formalin and in Carnua solution; paraffin sections of the large intestine were made; stained them with hematoxylin-eosin, alcian blue-carmine, or toluidine blue. Microscopic and morphometric analysis of these sections was performed. It has been shown, that obesity cause hyperactivation of the colonic mucosa, reduction of colonocytes, hypertrophy of goblet cells and overaccumulation of granules in mast cells. Morning administration of melatonin to obese animals normalizes the colonic mucosa, decreases the reduction of colonocytes, but causes the hypotrophy of goblet cells. Evening administration of melatonin significantly decreases the reduction of colonocytes, but does not eliminate other changes caused by obesity. The administration of melatonin (both morning and evening) to animals without obesity causes an activation of the mucosa, hypertrophy of goblet cells, reduction of colonocytes, and does not change the state of mast cells. Consequently, it cannot make a clear conclusion about the possibility of correction of all structural-functional changes in the large intestine during obesity by melatonin. Although, the morning administration of melatonin had some normalizing effects on the colon and it was more effective than evening administration.
The aim of this work was to determine structural and functional changes in a small intestine of rats after morning and evening administration of melatonin in obese animals during the spring-autumn photoperiod (12L:12D). The obesity was caused with a high-calorie diet for 6 weeks. After that, morning or evening melatonin administrations were given to normal and obese animals at a dose of 30 mg/kg for 7 weeks. After that, paraffin sections of the small intestine were made, on which a state of the mucosa, enterocytes and goblet cells in crypts was morphometrically and visually examined under a microscope. It has been shown, that obesity causes swelling and an increase of thickness of a mucosa, reduction of crypts, a decrease of activity of enterocytes and goblet cells of the small intestine. Introduction of melatonin to animals without obesity causes an increase in thickness of mucosa and a decrease in area of goblet cells. Additionally, after morning melatonin administration a depth of crypts and a height of enterocytes increases. Morning administration of melatonin to obese animals partially recovers crypts and their goblet cells, but doesn't prevent mucosal edema and worsens a state of enterocytes. The evening administration of melatonin partially normalizes all structural changes, caused by obesity. It was concluded, that melatonin may partially correct morpho-functional changes in the small intestine, caused by obesity in the spring and autumn seasons. The evening administration of melatonin to animals with obesity is more effective, than morning administrations. Also, the evening administration of melatonin causes fewer changes in the small intestine of animals without obesity, compared with morning administration.
1 Вінницький національний медичний університет імені М. І. Пирогова, м.Вінниця, Україна 2 Вінницький обласний клінічний високоспеціалізований ендокринологічний центр, м. Вінниця, Україна Мета роботи -визначити вплив комплексної терапії тіотриазоліну та L-лізину есцинату на інсулінорезистентність у хворих на неалкогольну жирову хворобу печінки (НАЖХП) з надлишковою масою тіла та ожирінням. Матеріал і методи. Обстежено 135 хворих на НАЖХП з надлишковою масою тіла та ожирінням, з них 46 -з надмірною масою 9 кг/ м2),9 кг/м2),9 кг/м2). Нормальну масу тіла (ІМТ-18-24,9 кг/м2) мали 35 пацієнтів. Обстежено також 20 практично здорових осіб. Вік обстежених варіював, медіана -55 років (міжквартильний розмах Q1-Q3 від 40 до 61 року). Верифікація діагнозу НАЖХП проводилася відповідно до рекомендацій уніфікованого клінічного протоколу. Результати. При додатковому призначенні тіотриазоліну та L-лізину есцинату концентрація АЛТ зменшилася в 1,81 раза до 38,16 (29,00-47,25) МО/л, АСТ в 1,70 раза до 35,76 (36,00-48,25) МО/л, а ГТТП -у 2,12 раза до 26,82 (24,00-30,25) МО/л, порівняно з показниками до лікування. та наближалися до показників у практично здорових осіб. Індекс НОМА знизився в 1,98 раза (при нормальній масі тіла), в 1,96 раза (при надлишковій масі тіла), у 2,35 раза (при ожирінні І ступеня), у 2,38 раза (при ожирінні ІІ ступеня). Додаткове призначення тіотриазоліну та L-лізину есцинату суттєво вплинуло на рівень інсуліну. Порівняно з періодом до лікування рівень інсуліну статистично значуще знизився не тільки у хворих на НАЖХП з надлишковою масою та ожирінням, а й у пацієнтів з нормальною масою тіла. Порівняно з базовою терапією рівень інсуліну у хворих на НАЖХП знизився на 22,37-40,54%. Індекс Caro після лікування збільшувався, що свідчить про позитивний вплив лікування на наявність інсулінорезистентності. Висновок. Комплексна базова терапія з додатковим застосуванням тіотриазоліну та L-лізину есцинату сприяє зменшенню інсулінорезистентності у хворих на неалкогольну жирову хворобу печінки з надлишковою масою тіла та ожирінням. Ключові слова: неалкогольна жирова хвороба печінки, лікування, тіотриазолін, L-лізину есцинат, інсулінорезистентність. Буковинський медичний вісник. Т.23, № 3 (91). С. 87-95. КОРРЕКЦИЯ ИНСУЛИНОРЕЗИСТЕНТНОСТИ У БОЛЬНЫХ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНЬЮ ПЕЧЕНИ С ИЗБЫТОЧНОЙ МАССОЙ ТЕЛА И ОЖИРЕНИЕМ Е. В. Пивторак, Н. А. Шевчук, Н. А. ПивторакКлючевые слова: неалкогольная жировая болезнь печени, лечение, тиотриазолин, L-лизина эсцинат, инсулинорезистентность. Цель работы -определить влияние комплексной терапии тиотриазолина и L-лизина эсцината на инсулинорезистентность у больных неалкогольной жировой болезнью печени (НАЖБП) с избыточной массой тела и ожирением. Материал и методы. Обследовано 135 больных НАЖБП с избыточной массой тела и ожирением, из них 46 -с избыточной массой 9 кг / м2),9 кг / м2),9 кг / м2). Нормальную массу тела (ИМТ-18-24,9 кг / м2) имели35 пациентов. Обследовано также 20 практически здоровых лиц. Возраст обследованных варьировал, медиана -55 лет (межквартильный УДК ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.